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Concerted overexpression of the genes encoding
p21 and cyclin D1 is associated with growth
inhibition and diVerentiation in various
carcinomas
J S de Jong, P J van Diest, R J A M Michalides, J P A Baak
Abstract
Aims—To investigate the expression of the
genes encoding cyclin D1 and p21 in
proliferative and non-proliferative cells,
as demonstrated by the Ki67 antibody, and
to correlate these findings with diVeren-
tiation.
Methods—Immunohistochemistry and
immunofluorescence double staining were
performed on three breast cancers, two
squamous cell cancers of the head and
neck, and one ovarium cystadenocarci-
noma. In addition, the in vitro eVect of
cyclin D1 on p21 gene expression in MCF7
breast cancer cells was evaluated.
Results—Immunofluorescence double
staining showed a diVerentiation related
gradient in the detection of the Ki67 anti-
gen, cyclin D1, and p21 in squamous cell
cancers of the head and neck: Ki67 was
detected in the basal layers of the tumour
and the cyclin D1 and p21 genes were
coexpressed in the higher, more diVeren-
tiated layers of the tumour. The breast and
ovarian cancers often had cells that coex-
pressed the p21 and cyclin D1 genes,
whereas coexpression of cyclin D1 and
Ki67 did not occur. Western blot analysis
of the MCF7 breast cancer cells showed an
upregulation of p21 production when cyc-
lin D1 gene expression was induced.
Conclusion—Overexpression of the cyclin
D1 gene seems to lead to growth arrest in
a variety of human cancers, possibly
through the induction of p21 by cyclin D1.
In squamous cell cancer, concerted over-
expression of the genes encoding cyclin D1
and p21 might also induce diVerentiation.
(J Clin Pathol: Mol Pathol 1999;52:78–83)
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Cell cycle progression in eukaryotes is control-
led by a series of proteins named cyclins. At
least eight cyclin genes have been identified in
mammalian cells. They are classified into three
groups: G1 cyclins, an A-type cyclin, and two
B-type cyclins. The genes encoding the G1
cyclins, cyclins D1–3 and cyclin E, are
expressed maximally during the G1 phase of
the cell cycle and regulate the transition of the
cell cycle from G1 into the S phase.1 2 Cyclin A
is mainly expressed in the late G1 and early S
phase and presumably enhances entry into and
transition through the S phase.3 The B-type
cyclins regulate entry into and exit from the
mitotic phase.4 The cyclins act by binding to
and stimulating the activities of a series of pro-
teins named the cyclin dependent kinases
(CDKs). At least six CDKs (CDK 1–6) have
been identified.5 CDK4 and CDK6 can associ-
ate with the D-type cyclins. The CDK4–cyclin
D1 complex plays a role in the transition from
the G1 to S phase by phosphorylation of the
retinoblastoma protein (pRb), thereby releas-
ing the transcription factor E2F. The discovery
of CDK kinase inhibitory (CKI) proteins has
provided a new paradigm for the control of cell
growth, which links the biochemical events
surrounding cell cycle arrest with various
physiological processes, including the cellular
response to DNA damage, response to growth
inhibitory signals, suppression of tumorigen-
esis, senescence, and diVerentiation.6 7 Two
families of CKIs have been described in mam-
malian cells. The p16 family, also known as the
INK4 family (inhibitor of CDK4) can only
inhibit CDK4–cyclin D and CDK6–cyclin D
complexes.8 The other family, the p21 family,
which includes p21cip1/waf1,9 p27kip1,10 and
p57kip2,11 can inhibit the activity of a variety of
CDK–cyclin kinase complexes. p21cip1/waf1 is
known to inhibit the kinase activity of the
CDK4–cyclin D1 complex.12 p21 regulates
cyclin–CDK activity by the number of bound
p21 molecules: active complexes contain a sin-
gle p21 molecule, whereas inactive complexes
contain multiple p21 molecules.13 p21 gene
expression can be regulated directly by the p53
tumour suppressor gene: the promoter region
of p21 contains two consensus p53 binding
sites.14 Introduction of p21 into malignant cells
can result in G1 phase arrest, altered morphol-
ogy, and cell diVerentiation.15
There is accumulating evidence for a dual
role of cyclin D1 in cell cycle control. Cyclin
D1 can promote progression through the G1
phase by associating with CDK4, which results
in phosphorylation of pRb, thereby releasing
E2F from the pRb–E2F complex. DiVerent
studies showed a shortened G1 phase in mouse
fibroblasts,16 rat cells,17 and breast cancer
cells,18 as a result of overexpression of the cyc-
lin D1 gene. One study on human breast can-
cer, however, showed an association between
overexpression of the cyclin D1 gene and high
telomerase activity without an increase in
tumour cell proliferation.19 In other studies,
cyclin D1 gene overexpression in HBL100
breast tumour cells could prolong the S phase,
which resulted in increased expression of
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â-casein in these cells,20 and inhibited DNA
replication,21 pointing to a growth restricting
function for cyclin D1. The latter observations
fit well with our previous finding that over-
expression of the cyclin D1 gene in invasive
breast cancer correlated negatively with prolif-
eration, as expressed by the number of mitotic
figures.22 In addition to the association between
overexpression of the cyclin D1 gene and a low
proliferation rate, cyclin D1 seemed to be
related to tumour diVerentiation because well
diVerentiated tumour types more often overex-
press the cyclin D1 gene than do poorly diVer-
entiated tumours.22–25 Alterations of the cyclin
D1 gene (also known as PRAD1, bcl-1),
located at chromosome 11q13, leading to
increased synthesis of the cyclin D1 protein,
have been found in many diVerent tumour
types, such as carcinomas of the breast,
oesophagus, bladder, liver, and stomach,
squamous carcinomas of the head and neck,26–28
parathyroid adenomas,29 and mantle cell
lymphomas.30–32 To investigate the association
between cyclin D1 and proliferation and
diVerentiation, we examined diVerent tumours
for their expression patterns of cyclin D1, p21,
and the proliferation associated protein Ki67.
In addition, we evaluated the in vitro eVect of
cyclin D1 on p21 gene expression in MCF7
breast cancer cells.
Material and methods
TUMOUR SPECIMENS
Fresh operation specimens from three invasive
breast cancers, two squamous cell cancers of
the head and neck, and one ovarium cystadeno-
carcinoma were cut into slices of ∼ 0.5 cm
thickness. These cancers were selected for their
cyclin D1 positivity. Tissues were fixed for at
least 24 hours in neutral buVered 10% formal-
dehyde. After paraYn wax embedding, 4 µm
thick sections were cut for routine staining with
haematoxylin and eosin, immunohistochemis-
try, and immunofluorescence.
IMMUNOHISTOCHEMISTRY
For immunohistochemistry, the sections were
mounted on 3-aminopropyltriethoxy silane
(APES; Sigma, Zayndrecht, The Netherlands)
coated slides. An avidin–biotin peroxidase
technique was used for staining the cyclin D1,
p21, p53, and Ki67 antigens. After the slides
were dewaxed, endogenous peroxidase activity
was blocked by incubation in 0.3% (vol/vol)
hydrogen peroxide in methanol for 30 minutes.
The slides were heated at 100°C in a 0.01 M
citrate buVer (pH 6.0) for 15 minutes for anti-
gen retrieval. Thereafter, the slides were prein-
cubated with normal rabbit serum (1/20) for
10 minutes. Subsequently, the slides were
incubated for 16 hours at 4°C with mouse
monoclonal antibodies against cyclin D1
(clone DCS-6, IgG2a; Novocastra, Newcastle,
UK; 1/40 dilution), p21 (clone 6B6, IgG1;
PharMingen, Los Angeles, California, USA;
1/200 dilution), p53 (clone DO-7; Dako, Glos-
trup, Denmark; 1/500 dilution), and Ki67
(Mib1, IgG1; Immunotech SA, Marseille,
France; 1/40 dilution). The slides were then
incubated with a biotinylated rabbit antimouse
antibody (1/500) for 30 minutes. The slides
were subsequently incubated with avidin–
biotinyl peroxidase complex (1/200) for one
hour. 3,3'-diaminobenzidine tetrahydrochlo-
ride (Sigma) was used as a chromogen.
Between steps, the slides were rinsed for 10
minutes in phosphate buVered saline (PBS)
three times. All sections were lightly counter-
stained with haematoxylin.
IMMUNOFLUORESCENCE DOUBLE STAINING
For double staining of cyclin D1/Ki67 and
cyclin D1/p21, the sections were pretreated as
for single staining (see above). Thereafter, sec-
tions were preincubated with normal goat
serum (1/20) for 10 minutes. Subsequently,
sections were incubated with a mixture of cyc-
lin D1 and Mib1 (both antibodies at a dilution
of 1/40) or cyclin D1 and p21 (1/40 and 1/200
dilutions, respectively) for 16 hours at 4°C.
Slides were reacted with isotype specific
secondary antibodies by incubation with a
mixture of horseradish peroxidase (HRP)
labelled goat antimouse IgG2a (1/50 dilution;
Southern Biotechnology, Birmingham, USA)
and biotin labelled goat antimouse IgG1 (1/50
dilution; Southern Biotechnology) for 30 min-
utes. Sections were incubated with fluorescein
isothiocyanate (FITC) labelled tyramine (1/10
dilution) for 20 minutes33 directed against the
goat antimouse IgG2a–HRP, resulting in a
green signal for cyclin D1 positive cells. There-
after, sections were incubated for one hour with
streptavidine–Cy3 (1/150 dilution; Jackson,
West Grave, USA) directed against the goat
antimouse IgG1–biotin, resulting in a red
signal for Ki67 and p21 positive cells. Sections
were counterstained with 4'6-diamidino-2-
phenylindol-2cHCl in Tris, pH 7.5 (DAPI;
Partec, Münster, Germany) for two minutes.
IMMUNOFLUORESCENCE MICROSCOPY
For visualising the Cy-3 and FITC immuno-
fluorescence signals a Leica DMRB immuno-
fluorescence microscope was used. A standard
Cy-3 filter (Leica filter cube N 2.1) was used
for visualising the Cy-3 signal and a standard
FITC filter (Leica filter cube L 4) was used for
visualising the FITC signal. A DAPI/FITC/
Cy-3 triple filter (Filter 61000; Chroma Tech-
nology, Vermont, USA) was used for visualis-
ing the Cy-3 (red), FITC (green), and DAPI
(blue) signals and the coexpression of Cy-3 and
FITC (yellow) in one view.
CELL CULTURE AND INDUCTION OF
OVEREXPRESSION OF THE CYCLIN D1 GENE
Human epithelial MCF7 breast tumour cells
and the cyclin D1 transfected MCF7 clone 3
cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with
10% fetal calf serum (FCS), 2 mM glutamine,
100 U/ml penicillin, and 100 µg/ml streptomy-
cin. The cyclin D1 transfected MCF7 clone 3
cells contained the pUHd15-1 and pSV2 neo–
tetracycline sensitive transactivator, the tet–
cyclin D1 plasmid, and the thymidine kinase–
hygromycin plasmid, as described previously.34
These cells were cultured in the presence of 10
µg/ml tetracycline to suppress the production
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of ectopic cyclin D1, whereas tetracycline was
omitted when overproduction of ectopic cyclin
D1 was wanted.
WESTERN BLOT ANALYSIS
MCF7 cells were cultured in medium with
10% FCS for 60 hours in the presence or
absence of tetracycline. Total cell extracts were
prepared by lysis of cell monolayers with
Laemmli sample buVer without bromophenol
blue. The protein concentration was measured
by the method of Lowry et al.35 Equal amounts
of protein (50 µg) were separated by sodium
dodecyl sulphate (SDS) polyacrylamide gel
electrophoresis and blotted on to a cellulose
nitrate membrane (Schleicher and Schuell).
Immunoblot analysis was performed on dif-
ferent strips of the membrane with an anti-pRb
(IF-8; Santa Cruz Biotechnology, Santa Cruz,
California, USA), anticyclin D1 (DCS-6; Pro-
gen, Newcastle, UK), anti-p21 (187; Santa
Cruz Biotechnology), and an antitubulin
monoclonal antibody (a kind gift of Dr S
Feltkamp, the Netherlands Cancer Institute) as
a control. Immunodetection was performed
with the enhanced chemiluminescence ECL
system (Amersham, Little Chalfont, UK).
Results
The single stained sections of the diVerent
tumour types showed the following results. In
squamous cell cancers, Ki67 was found in the
basal layers, whereas cyclin D1 and p21 were
seen exclusively in the higher layers of the
tumours. Immunofluorescence double staining
showed only occasional, low coexpression of
cyclin D1 and Ki67 in the basal layers
(probably at physiological levels). There was a
clear gradient in the detection of cyclin D1,
p21, and Ki67. The p21 and cyclin D1 strongly
positive cells were located in the higher layers
of the tumour, whereas the Ki67 positive cells
were in the basal layers of the tumour (fig 1).
Cyclin D1 and p21 genes were coexpressed in
many cells (fig 2). In addition, cells within the
breast and ovarian cancers often coexpressed
p21 and cyclin D1, whereas coexpression of
cyclin D1 and Ki67 did not occur.
The squamous cell cancers, ovarium cystad-
enocarcinoma, and one of the breast cancers
were positive for p53. The other two breast
cancers did not express p53.
Western blot analysis of the MCF7 breast
cancer cells showed an upregulation of p21
when cyclin D1 synthesis was induced (fig 3).
Expression of the cyclin D1 gene was induced
in MCF7 clone 3 cells by means of the tetracy-
cline regulated transcriptional activation
system,36 as described previously.34 The advan-
tage of using the tetracycline responsive
expression system is that results are not
influenced by clonal variation. Similar results
were obtained with another inducible clone of
cyclin D1 in MCF7 clone 8 cells. The concen-
tration of cyclin D1 seen in cells cultured in the
presence of tetracycline reflected the endog-
enous concentration of cyclin D1, whereas
omission of tetracycline from the medium
resulted in a five to sixfold overproduction of
cyclin D1 (fig 3). The extent of phosphoryla-
tion of pRb hardly diVered when the cells were
cultured in 10% FCS in the presence or
absence of tetracycline. The control, tubulin,
showed bands of a similar intensity in the pres-
ence and absence of tetracycline. However, p21
production changed drastically in MCF7 clone
3 cells, with overproduction of ectopic cyclin
D1 in comparison with cells with a normal
concentration of endogenous cyclin D1. The
raised p21 concentration in MCF7 clone 3
cells did not result in an altered cell cycle
distribution, because we did not see any
pronounced diVerences in the cell cycle distri-
bution of cells overexpressing the cyclin D1
gene compared with those not overexpressing
Figure 1 Immunofluorescence staining for cyclin D1 and Ki67 in a squamous cell carcinoma. (A) A gradient is seen for Ki67 positive cells (red), with
positive cells being found frequently in the basal layers of the epithelium and few being detected in the higher layers; (B) the opposite is seen for cyclin D1
(green). Faint basal staining is probably attributable to crossover from the blue DAPI staining. (C) In double staining experiments, only very few cells
stained for both Ki67 and cyclin D1 (yellow), with low (probably physiological) concentrations of cyclin D1 being detected.
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this gene (data not shown), nor in the growth
curves between these two types of cell.34
Discussion
In our study, we investigated the expression of
the cyclin D1 and p21 genes in proliferative
and non-proliferative cells, as demonstrated by
the Ki67 antibody. This study was stimulated
by the finding in previous studies of invasive
breast cancer that cyclin D1 seemed to be
associated with decreased proliferation and
with enhanced diVerentiation.22–25 These re-
sults pointed to a more complex role for cyclin
D1 in human tumours than is suggested by
other in vitro and in vivo studies, showing that
high concentrations of cyclin D1 render cell
growth independent of growth factors.34 37–39
In a previous study, we found raised concen-
trations of cyclin D1 in 59% of breast carcino-
mas, as detected by immunohistochemistry.
Most of these tumours were well differentiated,
characterised by oestrogen receptor positivity,
a high degree of tubule formation, small nuclei,
and a low proliferation rate, whereas the most
poorly diVerentiated tumours of the medullary
type, characterised by oestrogen receptor
negativity, solid growth, large atypical nuclei,
and a high proliferation rate, were consistently
cyclin D1 negative.22 In our present study, on
the single cell level, we found almost no cyclin
D1 in proliferating cells as marked by Ki67
staining. However, we did find a notable coex-
pression of the cyclin D1 and p21 genes in dif-
ferent tumour types. Furthermore, in
squamous cell cancers, we found a gradient
through the epithelium in the expression of
Ki67, cyclin D1, and p21, whereby the Ki67
positive proliferating cells were localised in the
basal layers of the epithelium, and the cyclin
D1 and p21 genes were coexpressed in the
higher layers of the epithelium. The localisa-
tion of cells overexpressing the cyclin D1 gene
in higher epithelial layers in squamous cell
cancers has been reported by others.40 41
Because cells overexpressing the cyclin D1
gene were almost all negative for Ki67 in our
study, high cellular concentrations of cyclin
D1, as demonstrated by immunohistochemis-
try, might not be associated with proliferation.
Rather, these cells seem to have undergone
proliferation arrest. In these cells, high concen-
trations of cyclin D1 may be related to
diVerentiation, as was shown in squamous cell
cancers, where cyclin D1 is produced mostly in
the higher, non-proliferating, diVerentiated
Figure 2 Immunofluorescence double staining of cyclin
D1 and p21 in a squamous cell carcinoma. (A) p21
positive cells (red) and (B) cyclin D1 positive cells (green)
are seen mainly in the higher, more diVerentiated layers of
the epithelium. Faint basal staining is probably attributable
to crossover from the blue DAPI staining. (C) Double
staining experiments show that many cells coexpress the
cyclin D1 and p21 genes (yellow).
Figure 3 Expression of the p21 gene after cyclin D1
induction in MCF7 clone 3 cells. Clone 3 cells were cultured
for 60 hours with (+) or without (−) induction of
exogenous cyclin D1 gene expression. Equal amounts of cell
lysate were separated on denaturing gels and subjected to
western blotting with antibodies against pRb, cyclin D1,
p21, and tubulin as described. The broad pRb band
indicates the position of hypophosphorylated and
hyperphosphorylated pRb. Note the upregulation of the p21
gene after induction of cyclin D1.
pRb
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layers of the epithelium. In the adenocarcino-
mas, this could not be studied because the dif-
ferentiation gradient as seen in squamous cell
cancers is lacking. This could be more closely
studied in raft cultures by transfecting cyclin
D1 with a controllable promoter. Nevertheless,
breast cancers with many cells overexpressing
cyclin D1 are generally well diVerentiated as
described above.
The cell cycle arrest and induction of diVer-
entiation in cells overexpressing the cyclin D1
gene might be a result of the induction of p21.
Coexpression of the cyclin D1 and p21 genes
was often seen in tumours positive for cyclin
D1. In these tumour cells, p21 might cause
proliferation arrest, thereby providing the
opportunity for cells to diVerentiate. The
involvement of p21 in the process of diVeren-
tiation has been shown in diVerent types of
cells.42–45 The results of the western blot analy-
sis of the MCF7 cells show an upregulation of
the p21 gene after induction of cyclin D1. This
result, and the results of others,46 indicate that
cyclin D1 might upregulate p21 expression.
However, the increased concentrations of p21
in cyclin D1 overexpressing cells does not
always lead to growth arrest in vitro,34 46
although high concentrations of cyclin D1 may
be “toxic”.16 In human cancers, this seems to
be diVerent. We suggest that a balance between
a positive regulator of the cell cycle, cyclin D1,
and a negative regulator, p21, is generated by a
feedback mechanism, where overexpression of
the cyclin D1 gene results in induction of p21.
By this mechanism, the eVects of overexpres-
sion of the cyclin D1 gene might be neutral-
ised, and the resulting proliferation arrest may
allow cells to diVerentiate. How overexpression
of the cyclin D1 gene is induced apart from
amplification or translocation is as yet un-
known, although growth factors have been
suggested to play a role.47 48 pRb deserves
attention in this respect because a previous
study showed that pRb stimulated by expres-
sion of the p21 gene may induce cyclin D1.49
In the tumours studied there were p21 posi-
tive cells that were cyclin D1 negative. This can
be explained by the fact that p21 may also be
induced by other proteins such as wild-type
p53. However, the ovarian cancer, the two
squamous cell cancers, and one of the breast
cancers that showed cells with strong coexpres-
sion of the p21 and cyclin D1 genes showed
strong nuclear staining for p53, which is highly
indicative of a mutation in the p53 gene.
Because mutant p53 is not able to induce
p21,12 50 the described mechanism seems to be
independent of p53. The expression of the p21
gene might also be upregulated through the
mitogen activated protein (MAP) kinase
pathway.51
Mutually exclusive expression of Ki67 and
p21 has also been reported for colonic
epithelium.42 The accumulation of p21 in
suprabasal layers in squamous cell head and
neck cancer was also reported by Erber et al,52
and did not coincide with Ki67 positive cells.
Remarkably, in that study, overexpression of
the p21 gene was reported to be indicative of
poor prognosis. Such an association with poor
prognosis was also found for overexpression of
the cyclin D1 gene in squamous cell head and
neck cancers,53 54 suggesting that the concerted
overproduction of two opposing regulators of
the cell cycle, cyclin D1 and p21, may be
indicative of poor prognosis in squamous cell
cancer of the head and neck. In our study we
looked at the single cell level and do not want
to speculate about the impact of the described
phenomena on the behaviour of tumours.
In conclusion, overexpression of the cyclin
D1 gene seems to lead to growth arrest in a
variety of human carcinomas, possibly through
the induction of p21 by cyclin D1. In
squamous cell cancer, a concerted overexpres-
sion of the genes encoding cyclin D1 and p21
might also induce diVerentiation. However, the
exact mechanisms of cyclin D1 overexpression
and p21 induction require further study.
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